Revvity (DB:PKN) - Stock Price, News & Analysis

PKN Stock Overview

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally.

About the company

PKN fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	1/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 53.3% below our estimate of its fair value

Earnings are forecast to grow 24.05% per year

Analysts in good agreement that stock price will rise by 23.9%

Risk Analysis

Large one-off items impacting financial results

Profit margins (6.5%) are lower than last year (15.5%)

Revvity, Inc. Competitors

SCHOTT Pharma KGaA

XTRA:1SXP

€5.7b

Sartorius

XTRA:SRT3

€16.9b

Gerresheimer

XTRA:GXI

€3.5b

Divi's Laboratories

NSEI:DIVISLAB

₹984.6b

Price History & Performance

Summary of all time highs, changes and price drops for Revvity
Historical stock prices
Current Share Price	US$92.62
52 Week High	US$123.15
52 Week Low	US$76.50
Beta	1.09
1 Month Change	-2.32%
3 Month Change	-4.28%
1 Year Change	-22.98%
3 Year Change	-16.93%
5 Year Change	10.38%
Change since IPO	571.16%

Recent updates

Shareholder Returns

	PKN	DE Life Sciences	DE Market
7D	-8.1%	-2.9%	-2.5%
1Y	-23.0%	-9.5%	-0.4%

Return vs Industry: PKN underperformed the German Life Sciences industry which returned -9.5% over the past year.

Return vs Market: PKN underperformed the German Market which returned -0.4% over the past year.

Price Volatility

Is PKN's price volatile compared to industry and market?
PKN volatility
PKN Average Weekly Movement	3.8%
Life Sciences Industry Average Movement	5.9%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	9.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: PKN has not had significant price volatility in the past 3 months.

Volatility Over Time: PKN's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1937	11,500	Prahlad Singh	www.revvity.com

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.

Revvity, Inc. Fundamentals Summary

How do Revvity's earnings and revenue compare to its market cap?
PKN fundamental statistics
Market cap	€11.67b
Earnings (TTM)	€168.64m
Revenue (TTM)	€2.58b

68.4x

P/E Ratio

4.5x

P/S Ratio

Is PKN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PKN income statement (TTM)
Revenue	US$2.75b
Cost of Revenue	US$1.21b
Gross Profit	US$1.54b
Other Expenses	US$1.36b
Earnings	US$179.50m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 29, 2024

Earnings per share (EPS)	1.45
Gross Margin	55.98%
Net Profit Margin	6.53%
Debt/Equity Ratio	49.5%

How did PKN perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

19%

Payout Ratio

Does PKN pay a reliable dividends?

See PKN dividend history and benchmarks

When do you need to buy PKN by to receive an upcoming dividend?
Revvity dividend dates
Ex Dividend Date	Apr 18 2024
Dividend Pay Date	May 10 2024
Days until Ex dividend	1 day
Days until Dividend pay date	21 days

Does PKN pay a reliable dividends?

See PKN dividend history and benchmarks

PKN Stock Overview

Rewards

Risk Analysis

Revvity, Inc. Competitors

XTRA:1SXP

€5.7b

XTRA:SRT3

€16.9b

XTRA:GXI

€3.5b

NSEI:DIVISLAB

₹984.6b

Price History & Performance

Recent News & Updates

Upcoming dividend of US$0.07 per share

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research

Full year 2023 earnings released: EPS: US$1.44 (vs US$4.06 in FY 2022)

Recent updates

Upcoming dividend of US$0.07 per share

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research

Full year 2023 earnings released: EPS: US$1.44 (vs US$4.06 in FY 2022)

Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

New minor risk - Earnings quality

Revvity Showcases Cutting-Edge Solutions at SLAS2024

Full year 2023 earnings released: EPS: US$1.44 (vs US$4.06 in FY 2022)

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Dividend of US$0.07 announced

Revvity, Inc., Annual General Meeting, Apr 23, 2024

Revvity, Inc. Announces Board Elections, Effective February 1, 2024

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024

Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

Investor sentiment improves as stock rises 15%

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

New major risk - Revenue and earnings growth

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.26 (vs US$0.55 in 3Q 2022)

Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries

New minor risk - Earnings quality

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.47 (vs US$1.33 in 2Q 2022)

Revvity Declares Quarterly Dividend, Payable on November 10, 2023

Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Upcoming dividend of US$0.07 per share at 0.2% yield

Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research

Revvity, Inc. Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development

First quarter 2023 earnings released: EPS: US$0.20 (vs US$1.40 in 1Q 2022)

Revvity, Inc. (NYSE:PKI) announces an Equity Buyback for $600 million worth of its shares.

Upcoming dividend of US$0.07 per share at 0.2% yield

Insufficient new directors

PerkinElmer, Inc. Provides Earnings Guidance for the Full Year of 2023

Full year 2022 earnings released: EPS: US$4.13 (vs US$8.12 in FY 2021)

PerkinElmer, Inc. Declares Regular Quarterly Dividend, Payable on May 12, 2023

Now 22% undervalued after recent price drop

Upcoming dividend of US$0.07 per share

PerkinElmer, Inc. to Report Q4, 2022 Results on Feb 14, 2023

Now 24% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: US$0.55 (vs US$0.94 in 3Q 2021)

PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns

Third quarter 2022 earnings released: EPS: US$0.55 (vs US$1.12 in 3Q 2021)

PerkinElmer, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

PerkinElmer, Inc. Declares a Regular Quarterly Dividend, Payable on February 10, 2023

PerkinElmer, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Upcoming dividend of US$0.07 per share

PerkinElmer, Inc. Unveils Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing

Perkinelmer’S Oxford Immunotec Receives U.S. Fda Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection

PerkinElmer, Inc. Announces Appointment of Maxwell Krakowiak as Senior Vice President, Effective September 6, 2022

Second quarter 2022 earnings released: EPS: US$1.42 (vs US$2.20 in 2Q 2021)

New Mountain Capital, L.L.C. entered into a definitive agreement with the intention to acquire Applied, Food and Enterprise Services businesses of PerkinElmer, Inc. (NYSE:PKI) for $2.5 billion.